Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma

Thyroid

Volumn 20, Issue 5, 2010, Pages 527-533

  Luster, Markus ^a   Karges, Wolfram ^b   Zeich, Katrin ^a   Pauls, Sandra ^a   Verburg, Frederik A ^c   Dralle, Henning ^d   Glatting, Gerhard ^a   Buck, Andreas K ^a   Solbach, Christoph ^a   Neumaier, Bernd ^a,e   Reske, Sven N ^a   Mottaghy, Felix M ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; CALCITONIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER LOCALIZATION; CANCER STAGING; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE ENDOCRINE NEOPLASIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGIST; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; CALCITONIN; CARCINOMA, MEDULLARY; CHILD; DIHYDROXYPHENYLALANINE; DISEASE PROGRESSION; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; YOUNG ADULT;

EID: 77952340573     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0342     Document Type: Article

References (19)

1. Gimm O, Sutter T, Dralle H 2001 Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma. J Cancer Res Clin Oncol 127:156-165.
2. Massoll N, Mazzaferri EL 2004 Diagnosis and management of medullary thyroid carcinoma. Clin Lab Med 24:49-83.
3. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA, Jr. 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612.
4. Unruh A, Fitze G, Jänig U, Bielack S, Lochbühler H, Coerdt W 2007 Medullary thyroid carcinoma in a 2-month-old male with multiple endocrine neoplasia 2B and symptoms of pseudo-Hirschprung disease: a case report. J Pediatr Surg 42:1623-1626.
5. Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E, Schlumberger M 2007 Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92:4185-4190.
6. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, Jager PL, Links TP 2008 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 49:524-531.
7. Sundin A, Eriksson B, Bergstrom M, Bjurling P, Lindner KJ, Oberg K, Langstrom B 2000 Demonstration of [11C]5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 27:33-41.
8. Garnett S, Firnau G, Nahmias C, Chirakal R 1983 Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res 280:169-171.
9. Reibring L, Agren H, Hartvig P, Tedroff J, Lundqvist H, Bjurling P, Kihlberg T, Langstrom B 1992 Uptake and utilization of [beta-11C]5- hydroxytryptophan in human brain studied by positron emission tomography. Psychiatry Res 45:215-225.
10. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E 2001 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64-71.
11. von Schulthess GK, Steinert HC, Hany TF 2006 Integrated PET/CT: current applications and future directions. Radiology 238:405-422.
12. de Vries EFJ, Luurtsema G, Brüssermann M, Elsinga PH, Vaalburg W 1999 Fully automated synthesis module for the high yield one-pot preparation of 6-[18F]fluoro-L-DOPA. Appl Radiat Isot 51:389-394.
13. Orlefors G, Sundin A, Lu L, Oberg K, Langstrom B, Eriksson B, Bergstrom M 2006 Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-f-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging 33:60-65.
14. Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, Ling A, Eisenhofer G, Adams KT, Pacak K 2007 The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 48:1599-1606.
15. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R 2000 A combined PET/CTscanner for clinical oncology. J Nucl Med 41:1369-1379.
16. Beheshti M, Pöcher S, Vali R, Waldenberg P, Broinger G, Nader M, Kohlfürst S, Pirich C, Dralle H, Langsteger W 2009 The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol 19:1425-1434.
17. Iagaru A, Masamed R, Singer PA, Conti PS 2007 Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol 9:72-77.
18. Hoefnagel CA 1994 Metaiodobenzylguanidine and somatostatin in oncology; role in the management of neural crest tumours. Eur J Nucl Med 21:561-581.
19. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E 1991 Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 64:567-573.